rs1801266
Variant summary
Our verdict is Likely pathogenic. The variant received 6 ACMG points: 6P and 0B. PM5PP3_Strong
The NM_000110.4(DPYD):c.703C>T(p.Arg235Trp) variant causes a missense change. The variant allele was found at a frequency of 0.0000477 in 1,613,280 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as drug response (★★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R235Q) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000110.4 missense
Scores
Clinical Significance
Conservation
Publications
- dihydropyrimidine dehydrogenase deficiencyInheritance: AR Classification: DEFINITIVE Submitted by: G2P
Genome browser will be placed here
ACMG classification
Our verdict: Likely_pathogenic. The variant received 6 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes  0.0000395  AC: 6AN: 151876Hom.:  0  Cov.: 32 show subpopulations 
GnomAD2 exomes  AF:  0.0000796  AC: 20AN: 251292 AF XY:  0.000118   show subpopulations 
GnomAD4 exome  AF:  0.0000486  AC: 71AN: 1461404Hom.:  0  Cov.: 30 AF XY:  0.0000619  AC XY: 45AN XY: 726998 show subpopulations 
Age Distribution
GnomAD4 genome  0.0000395  AC: 6AN: 151876Hom.:  0  Cov.: 32 AF XY:  0.0000270  AC XY: 2AN XY: 74164 show subpopulations 
Age Distribution
ClinVar
Submissions by phenotype
Dihydropyrimidine dehydrogenase deficiency    Pathogenic:1 
- -
fluorouracil response - Other    Other:1 
PharmGKB Level of Evidence 1A: Level 1A clinical annotations describe variant-drug combinations that have variant-specific prescribing guidance available in a current clinical guideline annotation or an FDA-approved drug label annotation. Annotations of drug labels or clinical guidelines must give prescribing guidance for specific variants (e.g. CYP2C9*3, HLA-B*57:01) or provide mapping from defined allele functions to diplotypes and phenotypes to be used as supporting evidence for a level 1A clinical annotation. Level 1A clinical annotations must also be supported by at least one publication in addition to a clinical guideline or drug label with variant-specific prescribing guidance. Drug-variant association: Other
Computational scores
Source: 
Splicing
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at